The Alpha Project

One day, genomic data will be translated into language that can be used to find new diagnostic and therapeutic targets for disease. Computers will mine DNA codes to build nanomachines, and "smart fabrics" will contain sensing capabilities modeled on living things. So says Shankar Shastry, chairman of electrical engineering and computer sciences at the University of California at Berkeley. "Bio is my bet on where the new set of glamour technologies will be," he predicts. But even the small step

Written bySteve Bunk
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

One day, genomic data will be translated into language that can be used to find new diagnostic and therapeutic targets for disease. Computers will mine DNA codes to build nanomachines, and "smart fabrics" will contain sensing capabilities modeled on living things. So says Shankar Shastry, chairman of electrical engineering and computer sciences at the University of California at Berkeley. "Bio is my bet on where the new set of glamour technologies will be," he predicts. But even the small steps that begin such giant leaps are hugely difficult to take. Witness the Alpha Project.

It's the brainchild of Roger Brent, president and research director of the Molecular Sciences Institute (MSI) in Berkeley, which was founded seven years ago by 2002 Nobelist Sydney Brenner as an independent, nonprofit research organization. Brent, a widely published former genetics professor at Massachusetts General Hospital and Harvard Medical School, joined MSI in 1998. Years before ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies